FDA-Industry GDUFA Reauthorization Meeting July 1, 2021, 10:00 am – 11:15 am Virtual Meeting

Purpose

To continue negotiations to reauthorize GDUFA (GDUFA III).

Participants

<u>FDA</u>		<u>Industry</u>	
Carter Beach	CDER	John DiLoreto	BPTF
Donald Beers	OC/OCC	David Gaugh	AAM
Lisa Berry	CDER	Karin Hessler	AAM
Ashley Boam	CDER	Kiran Krishnan	AAM (Apotex)
Joshua Brown	OC/OCC	Brian McCormick	AAM (Teva)
Jacqueline Corrigan-Curay	CDER	Lisa Parks	AAM
Alonza Cruse	ORA	Gil Roth	PBOA
Susan Rosencrance	CDER	Cornell Stamoran	PBOA (Catalent)
Bethany Rue	CDER	Molly Ventrelli	AAM (Fresenius-Kabi)
Edward Sherwood	CDER		
Maryll Toufanian	CDER		

FDA Supporting Staff

Tiana Barnes, Dat Doan, Andrew Fine, Tawni Schwemer, and Scott Vehovic

Discussion

FDA and Industry continued discussions around suitability petitions.

FDA shared a visual to show Industry the possible additive effects of goal dates when submitting post-midcycle meeting amendments.

Industry discussed a desire to continue to work on efficiencies around controlled correspondence.

Next Meeting

The next negotiation meeting will be Thursday, July 8, 2021.